Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (aut ...

Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The ...

SANTA MONICA, Calif., December 09, 2024--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus ...

(RTTNews) - Kite, a Gilead Company (GILD), said that the U.S. Food and Drug Administration has granted accelerated approval to Tecartus, the first and only approved chimeric antigen receptor or ...

(RTTNews) - Kite, a Gilead Co. (GILD), said Friday that the European Medicines Agency or EMA Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion for Tecartus ...

Cell therapies Yescarta and Tecartus posted major revenue increases of 70% and 40%, respectively, reaching sales of $359 million and $89 million during the first three months of the year.

The European Medicines Agency (EMA) today recommended granting conditional marketing authorization to KTE-X19 (Tecartus), making it the first approved chimeric antigen receptor (CAR) T-cell ...